Cost–effectiveness of rotavirus vaccines

References

• Parashar U, Hummelman E, Bresee J, Miller M, Glass R. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9, 565–572 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson N, Paredes S, Legorreta J, Ledogar RJ. Who pays for measles? The economic arguments for sustained immunization. Health Policy Plan. 7(4), 352–363 (1992).
   Web of Science ®Google Scholar
• Phillips MA, Feachem RG, Mills A. Options for diarrhoea control: the cost and cost–effectiveness of selected interventions for the prevention of diarrhoea. London School of Hygiene and Tropical Medicine, London, UK (1987).
   Google Scholar
• Word Health Organization. Report of the meeting on future directions for rotavirus vaccine research in developing countries. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2000).
   Google Scholar
• Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J. Infect. 45, 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Perez-Schael I. The impact of rotavirus disease in Venezuela. J. Infect. Dis. 174(Suppl. 1), S19–S21 (1996).
   Google Scholar
• De Vos B, Vesikari T, Linhares A et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, S179–S182 (2004).
   PubMed Web of Science ®Google Scholar
• Clark HF, Bernstein DI, Dennehy PH et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 144, 184–190 (2004).
   PubMed Web of Science ®Google Scholar
• Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar U, Rheingans R. Projected cost–effectiveness of rotavirus vaccination of children in Asia. J. Infect. Dis. 192(Suppl. 1), 133–145 (2005).
   PubMed Web of Science ®Google Scholar
• Beutels P, Edmunds J, Antonanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. PharmacoEconomics 20, 1–7 (2002).
   PubMed Web of Science ®Google Scholar
• Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J. 23, 32–37 (2004).
   PubMed Web of Science ®Google Scholar
• Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2002).
   Google Scholar
• Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust. NZ J. Public Health 23(6), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Takala AK, Koskenniemi E, Joensuu J, Makela M, Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin. Infect. Dis. 27(2), 272–282 (1998).
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Anderson GF, Powe NR et al. Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Arch. Pediatr. Adolesc. Med. 149(4), 407–414 (1995).
   PubMedGoogle Scholar
• Smith JC, Haddix JC, Teutsch SM, Glass RI. Cost–effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 96(4 Pt 1), 609–615 (1995).
   PubMed Web of Science ®Google Scholar
• Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost–effectiveness analysis of a rotavirus immunization program for the United States. JAMA 279(17), 1371–1376 (1998).
   PubMed Web of Science ®Google Scholar
• Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev. Panam. Salud Publica 10, 240–248 (2001).
   PubMedGoogle Scholar
• Miller M, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b, Streptococcus pneumoniae conjugate and rotavirus vaccines in national immunization schedules. Health Econ. 9, 19–35 (2000).
   PubMed Web of Science ®Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies. Health Econ. 10, 751–774 (2001).
   PubMed Web of Science ®Google Scholar
• Jamison D, Mosley W, Measham A, Bobadilla J. Disease Control Priorities in Developing Countries. Oxford University Press, NY, USA (1993).
   Google Scholar
• Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ. 16, 1–31 (1997).
   PubMed Web of Science ®Google Scholar
• England S, Loevinsohn B, Melgaard B, Kou U, Jha P. The evidence base for interventions to reduce mortality from vaccine-preventable diseases in low and middle-income countries. CMH Working Paper Series, number 10, Commission on Macroeconomics and Health, World Health Organization, Geneva, Switzerland (2001).
   Google Scholar
• Griffiths U, Rheingans R, Walker D. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the impact of rotavirus diarrhoea. World Health Organization, Department of Vaccines and Biologicals, Geneva, Switzerland (2005) (In Press)
   Google Scholar
• Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele, AD. Rotavirus vaccines: targeting the developing world. J. Infect. Dis. 192(Suppl. 1), 160–166 (2005).
   PubMed Web of Science ®Google Scholar
• Wecker J. Costs of a rotavirus vaccine. Science 307, 517–519 (2005).
   PubMed Web of Science ®Google Scholar